Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA09 in Relapsed/Refractory Autoimmune Disease
NCT06361745Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA09 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc) and 3 more, sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse Events at 3 months. Started Apr 2024; status: recruiting.
02
Drugs
UTAA09
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathies (IIM)systemic sclerosis (SSc)IgG4-related disease (IgG4-RD)primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT06361745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361745.